Stock·NYSE·Energy
Chevron Corporation (CVX)
- Market cap
- $441.34B
- P/E
- 21.37
- Dividend yield
- 3.13%
- Street target
- $227.50median of 25 analysts
- 52-week range
- $146.49 $225.31
The short version
Where CVX stands today, in four lines, and what CleaRank Financial AI makes of it.
CVX at a glance
Chevron Corporation (CVX): Strong Buy, 80/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($207.13 and $189.87).
- Earnings CVX beat estimates in 6 of its last 7 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $696.8M and made no open-market purchases over the last 18 months.
- Valuation P/E of 21.4 against 18.4 for the Energy sector: broadly in line with peers (+16%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Chevron Corporation (CVX) Strong Buy, with a model score of 80/100.
The trend lifts the score most: the price is 18.50% above its 200-day average and 8.62% above its 50-day average, and the 50-day average is 9.09% above the 200-day. The 50-day average stands at $207.13 and the 200-day at $189.87. Over the past year the price rose 48.30%.
Only on CleaRank
Figures we compute ourselves from CVX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $224.99 is 8.6% above the 50-day simple moving average of $207.13.Price above its 200-day average ›
The price is 18.5% above the 200-day simple moving average of $189.87.50-day average above the 200-day ›
The 50-day average ($207.13) is 9.1% above the 200-day average ($189.87), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 100% of its 52-week range, between $146.49 and $225.31.
CVX share price
Pick a period: each tab shows how far CVX has moved over it, to the last close.
Today's trading
Where CVX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 21.37 is 16.1% above the Energy median of 18.4.P/S below the sector median ›
The price-to-sales ratio of 2.08 is 16.8% below the sector median of 2.5.Profitable over the last 12 months ›
Net income over the last 12 months was $20.6B on revenue of $209.4B, a net margin of 9.8%.Beat estimates in most recent reports ›
CVX beat the EPS estimate in 6 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 3.13%, or $7.05 a share a year.
Key statistics
The headline figures for CVX.
As of October 17, 2026, CVX trades at $224.99, with a market value of $441.34B, a P/E ratio of 21.37 and a dividend yield of 3.13%.
What the numbers say
CleaRank Financial AI's reading of CVX's valuation, growth and risks.
CVX trades at 21.37 times trailing earnings, which is 16.1% above the Energy median P/E of 18.4. The peer comparison on this page rates that P/E as broadly in line with peers. Measured against sales, the P/S of 2.08 is 16.8% below the sector median of 2.5. The company's market value stands at $441.3B.
In the latest year revenue grew 53.50%, 20.7 percentage points faster than the sector median of 32.8%. CVX turns sales into profit at a net margin of 9.83% and an operating margin of 21.87%, alongside a return on equity of 12.23%, below the sector median of 14.2%. Debt-to-equity of 0.19 and a trailing dividend yield of 3.13% ($7.05 a share a year) round out the fundamentals.
CVX beat expectations in its July 31, 2026 report by 8.80%, posting EPS of $6.06 against the $5.57 that analysts had forecast. Still, the share price slipped 1.85% in the first session after the report.
CVX has beaten the EPS estimate in 6 of its last 7 reports. Still, the share price moved lower in the next session after 4 of those 6 beats. Analysts expect this fiscal year's average EPS to come in at $17.00, a rise of 133.2%. For next year they average $14.64, a fall of 13.9%.
CVX's average daily move comes to 1.45%. Insider sales over the last 18 months totalled $696.8M, and no open-market purchases were recorded. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market buying.
CVX against the Energy sector
How CVX compares with the median Energy stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (16% difference), suggesting fair market pricing relative to industry standards.
Return vs XLE: Since May 6, 2025, CVX has gained 65.9% against a gain of 68.9% for XLE.
Performance against XLE
CVX and the Energy sector fund over the same days.
Revenue and earnings
How much CVX sells, and how much of it becomes profit.
Revenue growth: Revenue fell 4.6% in FY2025 to $184B, from $193B a year earlier.
Profit margin: The net margin was 6.8% in FY2025, down from 9.2% the year before.
Profitable: CVX earned $12.5B in FY2025.
Earnings reality check
Did CVX beat what analysts expected, and how did the stock react?
Earnings record: CVX beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 4 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 31, 2026after close | $5.57 | $6.06 | +8.80% | -1.85% | -5.22% |
| May 1, 2026after close | $0.97 | $1.41 | +45.36% | +0.87% | -4.73% |
| Oct 31, 2025after close | $1.71 | $1.85 | +8.19% | -2.33% | -1.71% |
| Aug 1, 2025after close | $1.74 | $1.77 | +1.72% | -0.24% | +2.38% |
| May 2, 2025after close | $2.15 | $2.18 | +1.40% | -2.17% | -0.01% |
| Jan 31, 2025after close | $2.11 | $2.06 | -2.37% | +0.10% | +2.30% |
| Nov 1, 2024after close | $2.42 | $2.51 | +3.72% | +0.59% | +2.52% |
As of October 17, 2026, CVX has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 31, 2026, came in 8.80% above the estimate and the stock moved -1.85% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 70.8, in overbought territory.RSI above 50 ›
An RSI of 70.8 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CVX
The score, the reasoning behind it, and what could move the price next.
CVX is in an uptrend. Its price of $224.99 sits 18.50% above its 200-day average of $189.87 and 8.62% above its 50-day average of $207.13. The price is at 100% of its 52-week range, which puts it 0.14% below the 52-week high of $225.31. Meanwhile, the 50-day average is 9.09% above the 200-day average.
On momentum, the 14-day RSI reads 70.8, in overbought territory, with the MACD line positive. Every period on the chart shows a gain, with the price up 20.07% over the past three months, 22.28% over the past six months and 48.30% over the past year.
Earnings beat ›
The July 31, 2026 report beat the EPS estimate by 8.80%, and the share price fell 1.85% in the first session after it.
Source: Earnings report, July 31, 2026
Rating reaffirmed ›
UBS kept its Buy rating on October 8, 2026.
Source: Analyst action, UBS, October 8, 2026
- Keep an eye on the two closest levels. The 52-week high at $225.31 sits above the price, and the 20-day EMA at $212.48 sits below it.
- The 14-day RSI reads 70.8, which is in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- The share price dropped 1.85% in the first session after the July 31, 2026 report. Over the last 7 reports, CVX beat estimates in 6 of them.
CVX trades above its 50-day and 200-day moving averages ($207.13 and $189.87), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $212.48.
The 52-week high at $225.31 is the next level overhead. With the RSI in overbought territory, a pause would not end the trend by itself, but a drop back out of the bullish zone would show momentum fading.
Technical indicators
Momentum and trend for CVX, from its daily closes.
As of October 17, 2026, with CVX at $224.99, its 14-day RSI is 70.8 (overbought territory), its 50-day simple moving average is $207.13 and its 200-day is $189.87.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CVX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CVX's 1-year correlation of daily returns is +0.21 with S&P 500 (SPY), +0.09 with Nasdaq 100 (QQQ), -0.06 with Bitcoin (BTC) and -0.06 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
20 of 25 analysts rate it a buy or strong buy, 4 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $227.50 is 1.1% above the price.More buy ratings than three months ago ›
20 of 25 rate it a buy now, against 20 of 25 three months ago.
CVX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | UBS | Maintains | Buy |
| Sep 28, 2026 | TD Cowen | Maintains | Hold |
| Sep 25, 2026 | HSBC | Maintains | Buy |
| Sep 3, 2026 | BMO Capital | Maintains | Outperform |
| Sep 3, 2026 | Piper Sandler | Maintains | Overweight |
| Sep 3, 2026 | Wells Fargo | Maintains | Overweight |
As of October 17, 2026, 25 Wall Street analysts cover CVX: 20 rate it a buy or strong buy, 4 a hold and 1 a sell or strong sell. Their 12-month price targets range from $175.00 to $250.00, with a median of $227.50, 1.1% above the price of $224.99.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CVX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CVX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CVX tends to move, against the market and on its own.
The long record
CVX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.45% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 53.2%, from July 2019 to March 2020, regained by October 2021.Most 1-year holds ended higher ›
71% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $33,722, against $42,055 in the S&P 500 (SPY).
CVX Drawdowns & Recovery
As of October 17, 2026, CVX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -53.2% (July 2019 to March 2020); it regained that peak by October 2021, 19 months after the low, and 71% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CVX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CVX trailed the S&P 500 over this period: $33,722 against $42,055.
A $10,000 investment in CVX in October 2016 would be worth about $33,722 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CVX, and which have not.
Strongest month, November: an average of +6.70%, up in 9 of 10 years.
Weakest month, December: an average of -0.92%, up in 6 of 10 years.
This month, October: has averaged +0.45%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CVX's strongest calendar month has been November (average +6.70%, up in 9 of 10 years) and its weakest December (average -0.92%, up in 6 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CVX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CVX today could grow to about $19,892 by 2036 in the base case, with a 90th-percentile outcome near $66,049 and a 10th-percentile outcome around $5,991. The simulation models price only; at today's 3.13% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CVX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $296 for CVX by 2030 in the base case, from $225 today (1.3x over 4 years). The 10th-percentile path ends near $139. These are outcomes of a Monte Carlo simulation run on CVX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $165 | $241 | $352 | |
| 2028 | $151 | $258 | $442 | |
| 2029 | $143 | $277 | $534 | |
| 2030 | $139 | $296 | $633 | |
| 2031 | $136 | $317 | $741 |
Method: a lognormal simulation of CVX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CVX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought CVX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, CVX insiders reported 36 open-market sales worth $696.8M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Robert Hewitt Pate
Officer
|
Sell | 2.5K | $506.6K |
| Aug 17, 2026 | Andrew Benjamin Walz
Officer
|
Sell | 16.8K | $3.4M |
| Aug 17, 2026 | Dambisa F Moyo
Director
|
Grant | 350 | - |
| Aug 17, 2026 | Andrew Benjamin Walz
Officer
|
Option | 16.8K | $2.0M |
| Aug 14, 2026 | Michael K Wirth
Chief Executive Officer
|
Sell | 317.1K | $63.6M |
| Aug 14, 2026 | Michael K Wirth
Chief Executive Officer
|
Option | 317.1K | $28.0M |
| Aug 11, 2026 | Jeff B. Gustavson
Officer
|
Sell | 14.0K | $2.7M |
| Aug 11, 2026 | Jeff B. Gustavson
Officer
|
Option | 14.0K | $1.7M |
| Aug 5, 2026 | Michael K Wirth
Chief Executive Officer
|
Sell | 5.5K | $1.0M |
| Aug 3, 2026 | John B Hess Jr.
Director
|
Sell | 810.7K | $157.4M |
| Aug 3, 2026 | John B Hess Jr.
Director
|
Option | 709.4K | $50.3M |
| May 27, 2026 | Wanda M Austin
Director
|
Grant | 1.3K | - |
| May 27, 2026 | John B Frank
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Enriquejr Hernandez
Director
|
Grant | 1.3K | - |
| May 27, 2026 | John B Hess Jr.
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Marillyn A Hewson
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Thomas W Horton
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Jon M Huntsman Jr
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Dambisa F Moyo
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Debra L Reed-Klages
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Donald James Umpleby III
Director
|
Grant | 1.3K | - |
| May 27, 2026 | Cynthia J Warner
Director
|
Grant | 1.3K | - |
| May 20, 2026 | John B Hess Jr.
Director
|
Sell | 380.0K | $73.4M |
| May 6, 2026 | John B Hess Jr.
Director
|
Sell | 195.0K | $36.0M |
| May 6, 2026 | Dambisa F Moyo
Director
|
Grant | 780 | - |
| Mar 30, 2026 | Robert Hewitt Pate
Officer
|
Sell | 40.2K | $8.6M |
| Mar 30, 2026 | Robert Hewitt Pate
Officer
|
Option | 40.2K | $5.0M |
| Mar 6, 2026 | Robert Hewitt Pate
Officer
|
Sell | 47.2K | $9.1M |
| Mar 6, 2026 | Robert Hewitt Pate
Officer
|
Option | 47.2K | $5.3M |
| Mar 2, 2026 | Michael K Wirth
Chief Executive Officer
|
Sell | 272.6K | $51.6M |
| Mar 2, 2026 | Mark A. Nelson
Officer
|
Sell | 139.6K | $26.2M |
| Mar 2, 2026 | Robert Hewitt Pate
Officer
|
Sell | 93.5K | $17.5M |
| Mar 2, 2026 | Eimear P Bonner
Chief Financial Officer
|
Sell | 45.8K | $8.6M |
| Mar 2, 2026 | Andrew Benjamin Walz
Officer
|
Sell | 11.6K | $2.2M |
| Mar 2, 2026 | Eimear P Bonner
Chief Financial Officer
|
Option | 45.8K | $7.5M |
| Mar 2, 2026 | Mark A. Nelson
Officer
|
Option | 139.6K | $15.6M |
| Mar 2, 2026 | Robert Hewitt Pate
Officer
|
Option | 93.5K | $10.6M |
| Mar 2, 2026 | Andrew Benjamin Walz
Officer
|
Option | 11.6K | $1.2M |
| Mar 2, 2026 | Michael K Wirth
Chief Executive Officer
|
Option | 272.6K | $33.1M |
| Feb 27, 2026 | Jeff B. Gustavson
Officer
|
Sell | 6.7K | $1.2M |
| Feb 27, 2026 | Jeff B. Gustavson
Officer
|
Option | 6.7K | $835.7K |
| Feb 18, 2026 | Alana K. Knowles
Officer
|
Sell | 2.4K | $441.3K |
| Feb 18, 2026 | Andrew Benjamin Walz
Officer
|
Sell | 1.5K | $269.0K |
| Feb 13, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Sell | 12.2K | $2.2M |
| Feb 12, 2026 | Andrew Benjamin Walz
Officer
|
Sell | 666 | $122.1K |
| Feb 12, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Option | 10.6K | $1.2M |
| Feb 11, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Sell | 5 | $924 |
| Feb 10, 2026 | Eimear P Bonner
Chief Financial Officer
|
Grant | 5.0K | - |
| Feb 10, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Grant | 1.5K | - |
| Feb 10, 2026 | Jeff B. Gustavson
Officer
|
Grant | 1.9K | - |
| Feb 10, 2026 | Alana K. Knowles
Officer
|
Grant | 1.8K | - |
| Feb 10, 2026 | Robert Clay Neff Jr
Officer
|
Grant | 3.6K | - |
| Feb 10, 2026 | Mark A. Nelson
Officer
|
Grant | 7.0K | - |
| Feb 10, 2026 | Robert Hewitt Pate
Officer
|
Grant | 4.8K | - |
| Feb 10, 2026 | Andrew Benjamin Walz
Officer
|
Grant | 2.2K | - |
| Feb 10, 2026 | Michael K Wirth
Chief Executive Officer
|
Grant | 19.6K | - |
| Feb 3, 2026 | Andrew Benjamin Walz
Officer
|
Sell | 22.2K | $3.9M |
| Feb 3, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Sell | 6.0K | $1.1M |
| Feb 3, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Option | 6.0K | $678.1K |
| Feb 3, 2026 | Andrew Benjamin Walz
Officer
|
Option | 22.2K | $2.6M |
| Feb 2, 2026 | Mark A. Nelson
Officer
|
Sell | 45.8K | $8.0M |
| Feb 2, 2026 | Mark A. Nelson
Officer
|
Option | 62.1K | $5.6M |
| Jan 30, 2026 | Robert Hewitt Pate
Officer
|
Sell | 41.1K | $7.3M |
| Jan 30, 2026 | Eimear P Bonner
Chief Financial Officer
|
Sell | 32.1K | $5.6M |
| Jan 30, 2026 | Eimear P Bonner
Chief Financial Officer
|
Option | 40.8K | $4.3M |
| Jan 30, 2026 | Thomas Ryder Booth
Chief Technology Officer
|
Grant | 3.6K | - |
| Jan 30, 2026 | Jeff B. Gustavson
Officer
|
Grant | 3.8K | - |
| Jan 30, 2026 | Alana K. Knowles
Officer
|
Grant | 3.4K | - |
| Jan 30, 2026 | Robert Clay Neff Jr
Officer
|
Grant | 11.8K | - |
| Jan 30, 2026 | Robert Hewitt Pate
Officer
|
Option | 53.5K | $3.6M |
| Jan 30, 2026 | Andrew Benjamin Walz
Officer
|
Grant | 4.8K | - |
| Jan 30, 2026 | Michael K Wirth
Chief Executive Officer
|
Grant | 60.7K | - |
| Jan 28, 2026 | Eimear P Bonner
Chief Financial Officer
|
Sell | 7.5K | $1.3M |
| Jan 28, 2026 | Alana K. Knowles
Officer
|
Sell | 3.2K | $544.0K |
| Jan 28, 2026 | Eimear P Bonner
Chief Financial Officer
|
Option | 7.5K | $831.5K |
| Jan 28, 2026 | Alana K. Knowles
Officer
|
Option | 3.2K | $424.6K |
| Jan 27, 2026 | Thomas W Horton
Director
|
Grant | 458 | - |
| Jan 14, 2026 | Alana K. Knowles
Officer
|
Sell | 3.2K | $537.6K |
| Jan 14, 2026 | Alana K. Knowles
Officer
|
Option | 3.2K | $424.6K |
| Jan 5, 2026 | Michael K Wirth
Chief Executive Officer
|
Sell | 320.7K | $52.3M |
| Jan 5, 2026 | Eimear P Bonner
Chief Financial Officer
|
Sell | 28.3K | $4.7M |
| Jan 5, 2026 | Alana K. Knowles
Officer
|
Sell | 8.0K | $1.3M |
| Jan 5, 2026 | Eimear P Bonner
Chief Financial Officer
|
Option | 28.3K | $2.5M |
| Jan 5, 2026 | Alana K. Knowles
Officer
|
Option | 8.0K | $701.7K |
| Jan 5, 2026 | Michael K Wirth
Chief Executive Officer
|
Option | 320.7K | $29.5M |
| Dec 17, 2025 | Eimear P Bonner
Chief Financial Officer
|
Grant | 102 | - |
| Dec 17, 2025 | Thomas Ryder Booth
Chief Technology Officer
|
Grant | 122 | - |
| Dec 17, 2025 | Jeff B. Gustavson
Officer
|
Grant | 46 | - |
| Dec 17, 2025 | Alana K. Knowles
Officer
|
Grant | 86 | - |
| Dec 17, 2025 | Robert Clay Neff Jr
Officer
|
Grant | 143 | - |
| Dec 17, 2025 | Mark A. Nelson
Officer
|
Grant | 269 | - |
| Dec 17, 2025 | Robert Hewitt Pate
Officer
|
Grant | 190 | - |
| Dec 17, 2025 | Andrew Benjamin Walz
Officer
|
Grant | 72 | - |
| Dec 17, 2025 | Michael K Wirth
Chief Executive Officer
|
Grant | 836 | - |
| Nov 21, 2025 | John B Hess Jr.
Director
|
Sell | 550.0K | $82.7M |
| Nov 21, 2025 | Jeff B. Gustavson
Officer
|
Sell | 9.3K | $1.4M |
| Nov 21, 2025 | Jeff B. Gustavson
Officer
|
Option | 9.3K | $776.7K |
| Nov 20, 2025 | Dambisa F Moyo
Director
|
Grant | 662 | - |
| Aug 29, 2025 | Alana K. Knowles
Officer
|
Sell | 4.0K | $636.5K |
| Aug 29, 2025 | Alana K. Knowles
Officer
|
Option | 4.0K | $350.9K |
| Aug 22, 2025 | John B Hess Jr.
Director
|
Sell | 375.0K | $59.4M |
| Aug 6, 2025 | Dambisa F Moyo
Director
|
Grant | 495 | - |
| Jul 28, 2025 | John B Hess Jr.
Director
|
Grant | 1.3K | - |
| Jul 18, 2025 | Marillyn A Hewson
Director
|
Grant | 59 | - |
| Jul 18, 2025 | Robert Hewitt Pate
General Counsel
|
Grant | 20 | - |
| Jul 18, 2025 | Debra L. Reed-Klages
Director
|
Grant | 316 | - |
| Jul 18, 2025 | Donald James Umpleby III
Director
|
Grant | 9 | - |
| Jul 18, 2025 | Michael K Wirth
Chief Executive Officer
|
Grant | 51 | - |
| May 28, 2025 | Wanda M Austin
Director
|
Grant | 1.7K | - |
| May 28, 2025 | John B Frank
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Alice P Gast
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Enriquejr Hernandez
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Marillyn A Hewson
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Jon M Huntsman Jr
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Charles W Moorman IV
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Dambisa F Moyo
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Debra L Reed-Klages
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Donald James Umpleby III
Director
|
Grant | 1.7K | - |
| May 28, 2025 | Cynthia J Warner
Director
|
Grant | 1.7K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.